A Study to Evaluate SAGE-217 in Participants With Parkinson's Disease
Status:
Completed
Trial end date:
2017-09-11
Target enrollment:
Participant gender:
Summary
This study assesses the safety, tolerability, pharmacokinetics and efficacy of SAGE-217 in 29
participants with moderate to severe Parkinson's Disease.